Fulcrum Therapeutics Inc logo

FULC

Fulcrum Therapeutics Inc

$7.81

Earnings Summary

Revenue
$2.59Mn
Net Profits
$-25.93Mn
Net Profit Margins
-1000.31%

Highlights

Revenue:

Fulcrum Therapeutics Inc’s revenue fell -45.88% since last year same period to $2.59Mn in the Q1 2022. On a quarterly growth basis, Fulcrum Therapeutics Inc has generated -48.75% fall in its revenue since last 3-months.

Net Profits:

Fulcrum Therapeutics Inc’s net profit fell -52.53% since last year same period to $-25.93Mn in the Q1 2022. On a quarterly growth basis, Fulcrum Therapeutics Inc has generated -10.41% fall in its net profits since last 3-months.

Net Profit Margins:

Fulcrum Therapeutics Inc’s net profit margin fell -181.81% since last year same period to -1000.31% in the Q1 2022. On a quarterly growth basis, Fulcrum Therapeutics Inc has generated -115.45% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Fulcrum Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.66
EPS Estimate Current Year
-0.66

Highlights

EPS Estimate Current Quarter:

Fulcrum Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -0.66 - a -4.76% fall from last quarter’s estimates.

EPS Estimate Current Year:

Fulcrum Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -0.66.

Key Ratios

Key ratios of the Fulcrum Therapeutics Inc post its Q1 2022 earnings

Earning Per Share (EPS)
-0.64
Return on Assets (ROA)
-0.39
Return on Equity (ROE)
-0.77
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Fulcrum Therapeutics Inc’s earning per share (EPS) fell -18.52% since last year same period to -0.64 in the Q1 2022. This indicates that the Fulcrum Therapeutics Inc has generated -18.52% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Fulcrum Therapeutics Inc’s return on assets (ROA) stands at -0.39.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Fulcrum Therapeutics Inc’s return on equity (ROE) stands at -0.77.

Dividend Per Share (DPS):

Fulcrum Therapeutics Inc declared 0 dividend per share during the earnings announcement for Q1 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-09
-0.63
-0.64
-1.59%

Company Information

Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum's proprietary product engine identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The company has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta thalassemia into Phase 1 clinical development.

Organisation
Fulcrum Therapeutics Inc
Employees
73
Industry
Health Technology